Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 5, 2023 /PRNewswire/ -- Sirnaomics Ltd. , a leading biopharmaceutical company engaging in discovery and development of advanced RNAi...
United States Francois Lebel Sirnaomic Galahead Patrick Lu Group Or Sirnaomics Group Factor Xi Program
Source: marketscreener.com